Compare Ascendis Pharma A/S (ASND) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs LTC Properties Inc — how do they compare? Ascendis Pharma A/S trades at $255.71 (market cap $16.67B), while LTC Properties Inc trades at $38.47 (market cap $2.05B). The key difference: Ascendis Pharma A/S is far larger — about 8.1× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LTC | |
|---|---|---|
Market Cap | $16.67B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $42.81 |
52-Week Low | $189.74 | $33.98 |
Enterprise Value | $17.04B | $2.79B |
Dividend Yield | — | 5.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
LTC Properties (LTC) trades at $38.32, down 2.79% over 24 hours, with a bullish technical signal driven by moving averages. The REIT shows strong profitability with a 61.72% gross margin and 38.93% net margin, though recent earnings missed estimates in two of the last three quarters. Recent news highlights aggressive expansion in seniors housing acquisitions, including a $95 million SHOP purchase announced August 5, 2026.
Outlook is mixed: demographic trends support long-term demand, but execution risks from rapid growth and debt-funded investments pose challenges. Analysts are cautious with 59% hold ratings, reflecting concerns over earnings consistency amid high capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
